MY160572A - A combination composition - Google Patents

A combination composition

Info

Publication number
MY160572A
MY160572A MYPI2013001237A MYPI2013001237A MY160572A MY 160572 A MY160572 A MY 160572A MY PI2013001237 A MYPI2013001237 A MY PI2013001237A MY PI2013001237 A MYPI2013001237 A MY PI2013001237A MY 160572 A MY160572 A MY 160572A
Authority
MY
Malaysia
Prior art keywords
approximately
combination
combination composition
paracetamol
ibuprofen
Prior art date
Application number
MYPI2013001237A
Other languages
English (en)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MY160572A publication Critical patent/MY160572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
MYPI2013001237A 2010-11-04 2011-10-26 A combination composition MY160572A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04

Publications (1)

Publication Number Publication Date
MY160572A true MY160572A (en) 2017-03-15

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013001237A MY160572A (en) 2010-11-04 2011-10-26 A combination composition

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN107519159A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ,インコーポレーテッド 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
ES2651444T3 (es) * 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201906742T4 (tr) * 2008-10-14 2019-05-21 Aft Pharmaceuticals Ltd Tıbbi bir ürün ve tedavi.
AU2010224063B2 (en) * 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
NZ604009A (en) * 2010-07-07 2015-03-27 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛

Also Published As

Publication number Publication date
US20160235695A1 (en) 2016-08-18
LT2635269T (lt) 2019-09-10
PH12013500689A1 (en) 2013-05-27
KR101900520B1 (ko) 2018-09-19
US11896567B2 (en) 2024-02-13
PT2635269T (pt) 2019-09-04
CA2814057A1 (en) 2012-05-10
MX2013005113A (es) 2013-06-03
EP2635269B1 (en) 2019-05-22
HUE045442T2 (hu) 2019-12-30
US20250134839A1 (en) 2025-05-01
MX367209B (es) 2019-07-22
JP6353577B2 (ja) 2018-07-04
PH12021550804A1 (en) 2022-02-14
ES2742373T3 (es) 2020-02-14
SMT201900481T1 (it) 2019-11-13
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
RU2707089C2 (ru) 2019-11-22
AU2011324137A1 (en) 2013-05-02
US20240207210A1 (en) 2024-06-27
CY1123398T1 (el) 2021-10-29
RU2015103107A (ru) 2015-06-20
CN107519159A (zh) 2017-12-29
US11446266B2 (en) 2022-09-20
PL2635269T3 (pl) 2019-11-29
RU2013123646A (ru) 2014-12-10
HRP20191489T1 (hr) 2019-11-15
BR112013010829B1 (pt) 2021-12-21
CL2013001250A1 (es) 2013-08-30
EP2635269A4 (en) 2014-09-17
RS59258B1 (sr) 2019-10-31
US20130225685A1 (en) 2013-08-29
JP2017132791A (ja) 2017-08-03
KR20140025314A (ko) 2014-03-04
AU2011324137B2 (en) 2015-05-07
CA2814057C (en) 2022-02-01
DK2635269T3 (da) 2019-08-26
NZ609727A (en) 2015-07-31
US12220392B2 (en) 2025-02-11
JP2013541583A (ja) 2013-11-14
SI2635269T1 (sl) 2019-10-30
CO6771406A2 (es) 2013-10-15
WO2012060719A1 (en) 2012-05-10
SG189319A1 (en) 2013-05-31
CN103298464A (zh) 2013-09-11
EP2635269A1 (en) 2013-09-11
US20230000805A1 (en) 2023-01-05
RU2015103107A3 (enExample) 2018-08-20
BR112013010829B8 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
PH12021550804A1 (en) A combination composition
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
MY173215A (en) Acetylcysteine compositions and methods of use thereof
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
GB0807605D0 (en) Lipid composition
MX2010010026A (es) Agente para tratar enfermedad.
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IN2014DN08598A (enExample)
PH12020551726A1 (en) Treatment of atopic dermatitis
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
WO2009012472A3 (en) Methods and compositions for treating conditions
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
TN2015000156A1 (en) Dispersible tablet
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
MX2015013911A (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
MX2010007607A (es) (e)-n-{3-[1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] ciclohepten-5iliden)-propil}-fenil}-metilsulfon amida como modulador de receptor glucocorticoide para el tratamiento de reumatoide.